["Taxanes: an action mechanism at the cellular level, significant clinical progress in the treatment of cancers of the ovary and breast"].
The past decade has witnessed the development of a new class of cytotoxic agents with a new mechanism of action: the Taxanes. These compounds promote tubulin assembly in microtubules and inhibit their depolymerisation; as a result, they compromise a number of vital cellular functions in which microtubules play a critical role; of note, is the fact that they seem to be relatively "p53 independent", contrary to many cytotoxic agents in current clinical use. Taxol represents a "breakthrough" in the treatment of ovarian cancer, and Taxotere is a major step forward in the treatment of breast cancer. The Jules Bordet Institute has actively contributed to the clinical development of these two compounds in these two indications.